EMD Serono to Adopt Revised and Strengthened ... ( - Revised Code Demonstrates Stron...)

EMD Serono to Adopt Revised and Strengthened PhRMA Code

Date:7/10/2008

- Revised Code Demonstrates Strong Commitment to Ethical Information

Exchange between Physician Community and Leading Biotechnology and

Pharmaceutical Companies -

ROCKLAND, Mass., July 10 /PRNewswire/ -- EMD Serono, Inc. announced today that the company has adopted and will fully implement, the revised and strengthened PhRMA Code on Interactions with Healthcare Professionals. The revised voluntary Code, which builds on the prior 2002 version, was approved unanimously by the PhRMA Board of Directors and announced by PhRMA earlier today. The revised Code reaffirms that interactions between company representatives and healthcare professionals should be focused on informing healthcare professionals about the benefits and risks of medicines to help enhance patient care, providing scientific and educational information, and supporting medical research and takes effect in January 2009. The revised Code reinforces the commitment of America's leading pharmaceutical research and biotechnology companies, including EMD Serono, to provide up-to-date, accurate information to healthcare providers about life-saving and life-enhancing medicines.

The adoption of the revised Code reaffirms EMD Serono's pledge to focus interactions between company representatives and healthcare professionals on informing them of our products and advancing tomorrow's medicines. EMD Serono adopted the prior version of the Code in 2002 and actively worked with PhRMA on enhancements to the Code. EMD Serono fully supports the underlying purpose of the enhanced Code to ensure that interactions between industry and healthcare professionals meet the highest ethical standards and benefit patients. EMD Serono has implemented a comprehensive company-wide Compliance Program; introduction of the revised PhRMA code aligns with the company's commitment to best practices and ethics in serving the medical community and patients.

"EMD Serono was an early cont
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
2. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
3. EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
4. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
5. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
6. Coley Pharmaceutical Group Adopts Shareholder Rights Plan
7. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
8. Monsanto Company Executives Adopt 10b5-1 Trading Plans
9. YM Biosciences announces adoption of renewed Shareholders Rights Plan
10. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
11. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress

Post Your Comments:

EMD Serono to Adopt Revised and Strengthened ...( - Revised Code Demonstrates Stron...)